Profile
Knud Aunstrup worked as a Director at Nuevolution AB from 2000 to 2012.
He also worked as a Vice President-Enzyme Research at Novo Nordisk A and as a President at Novo Nordisk China.
Former positions of Knud Aunstrup
| Companies | Position | End |
|---|---|---|
| NUEVOLUTION AB (PUBL) | Director/Board Member | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Novo Nordisk China
 Novo Nordisk China Medical SpecialtiesHealth Technology Part of Novo Nordisk Fonden, Novo Nordisk China is a Chinese global biopharmaceutical company headquartered in Copenhagen, Denmark. The company is based in Beijing, China. The company's goal is to drive change in order to overcome serious chronic diseases such as diabetes, obesity, rare blood diseases, and endocrine disorders. | President | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| Private companies | 2 |
|---|---|
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
Novo Nordisk China
Novo Nordisk China Medical SpecialtiesHealth Technology Part of Novo Nordisk Fonden, Novo Nordisk China is a Chinese global biopharmaceutical company headquartered in Copenhagen, Denmark. The company is based in Beijing, China. The company's goal is to drive change in order to overcome serious chronic diseases such as diabetes, obesity, rare blood diseases, and endocrine disorders. | Health Technology |
- Stock Market
- Insiders
- Knud Aunstrup